Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2 2Phase 1 2Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 11INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Vomiting 2Nausea 2Neoplasms 1Breast Neoplasms 1

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × Aprepitant × Clear all
NCT01636947 2018-09-25

KMEC

Merck Sharp & Dohme LLC

Phase 4 Completed
494 enrolled 14 charts

Nausea, Neoplasms, Vomiting

NCT00092183 2017-05-05

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

Merck Sharp & Dohme LLC

Phase 4 Completed
866 enrolled
Breast

Breast Neoplasms, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡